Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis

Accepted/In Press date: 13 May 2022

e-pub ahead of print date: 18 May 2022

Published date: July 2022

Additional Information: Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.H. Knudsen, H.B.W. Larsson & S.P. Cramer received funding from Sanofi Genzyme and The Danish Multiple Sclerosis Society. Sanofi Genzyme had no influence on the study design, inclusion of patients, data analysis or interpretation. U. Lindberg, M.B. Vestergaard, H.J. Simonsen & I. Galea have nothing to disclose. J.L. Frederiksen received no funding to support this study. She has served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, Novartis and Almirall. She has received speaker honoraria from Biogen Idec, Teva and Novartis. She has served as advisor on preclinical development for Takeda. J.L Frederiksen participate in advisory board meetings with Alexion and Chiesi. A. Varatharaj is funded by the National Institute for Health Research (UK), and has received travel funding from Teva. F.T. Sellebjerg has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi Genzyme. His laboratory has received research support from Biogen , Merck, Novartis, Roche and Sanofi Genzyme. M. Blinkenberg reports personal fees from Sanofi Genzyme, personal fees from Biogen, personal fees from Merck, personal fees from Novartis, personal fees from Teva, personal fees from Roche, personal fees from Bristol Myers Squibb, nonfinancial support from Biogen , nonfinancial support from Roche , and nonfinancial support from Genzyme , outside the submitted work. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.H. Knudsen, H.B.W. Larsson & S.P. Cramer received funding from Sanofi Genzyme and The Danish Multiple Sclerosis Society. Sanofi Genzyme had no influence on the study design, inclusion of patients, data analysis or interpretation. U. Lindberg, M.B. Vestergaard, H.J. Simonsen & I. Galea have nothing to disclose. J.L. Frederiksen received no funding to support this study. She has served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, Novartis and Almirall. She has received speaker honoraria from Biogen Idec, Teva and Novartis. She has served as advisor on preclinical development for Takeda. J.L Frederiksen participate in advisory board meetings with Alexion and Chiesi. A. Varatharaj is funded by the National Institute for Health Research (UK), and has received travel funding from Teva. F.T. Sellebjerg has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. M. Blinkenberg reports personal fees from Sanofi Genzyme, personal fees from Biogen, personal fees from Merck, personal fees from Novartis, personal fees from Teva, personal fees from Roche, personal fees from Bristol Myers Squibb, nonfinancial support from Biogen, nonfinancial support from Roche, and nonfinancial support from Genzyme, outside the submitted work.This investigator-sponsored study was supported by Sanofi Genzyme [Grant number GZ-2016–11,629] and The Danish Multiple Sclerosis Society [Grant numbers A37989, A40212, A41682]. The funding bodies had no influence on the study design, inclusion of patients, data analysis, interpretation or writing of the final manuscript.The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: M.H. Knudsen, H.B.W. Larsson & S.P. Cramer received funding from Sanofi Genzyme and The Danish Multiple Sclerosis Society. Sanofi Genzyme had no influence on the study design, inclusion of patients, data analysis or interpretation. U. Lindberg, M.B. Vestergaard, H.J. Simonsen & I. Galea have nothing to disclose. J.L. Frederiksen received no funding to support this study. She has served on scientific advisory boards for and received funding for travel related to these activities as well as honoraria from Biogen Idec, Merck Serono, Sanofi-Aventis, Teva, Novartis and Almirall. She has received speaker honoraria from Biogen Idec, Teva and Novartis. She has served as advisor on preclinical development for Takeda. J.L Frederiksen participate in advisory board meetings with Alexion and Chiesi. A. Varatharaj is funded by the National Institute for Health Research (UK), and has received travel funding from Teva. F.T. Sellebjerg has served on scientific advisory boards for, served as consultant for, received support for congress participation or received speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche and Sanofi Genzyme. His-laboratory has received research support from Biogen, Merck, Novartis, Roche and Sanofi Genzyme. M. Blinkenberg reports personal fees from Sanofi Genzyme, personal fees from Biogen, personal fees from Merck, personal fees from Novartis, personal fees from Teva, personal fees from Roche, personal fees from Bristol Myers Squibb, nonfinancial support from Biogen, nonfinancial support from Roche, and nonfinancial support from Genzyme, outside the submitted work. Funding Information: This investigator-sponsored study was supported by Sanofi Genzyme [Grant number GZ-2016–11,629] and The Danish Multiple Sclerosis Society [Grant numbers A37989, A40212, A41682]. The funding bodies had no influence on the study design, inclusion of patients, data analysis, interpretation or writing of the final manuscript. Publisher Copyright: © 2022

Keywords: Alemtuzumab, Biomarker, MRI, Neuroimaging, Relapsing-remitting multiple sclerosis

Local EPrints ID: 467982

URI: http://eprints.soton.ac.uk/id/eprint/467982

DOI: doi:10.1016/j.msard.2022.103891

ISSN: 2211-0348

PURE UUID: a4047550-335f-46da-bb84-f67db66fb0aa

ORCID for Aravinthan Varatharaj: orcid.org/0000-0003-1629-5774

ORCID for Ian Galea: orcid.org/0000-0002-1268-5102

Date deposited: 27 Jul 2022 16:50

Last modified: 17 Mar 2024 03:53